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Abstract
Background: To describe frequency, preventability and seriousness of adverse drug reactions (ADRs) in children as
cause of emergency department (ED) admission and to evaluate the association between specific factors and the
reporting of ADRs.
Methods: A retrospective analysis based on reports of suspected ADRs collected between January 1st, 2012 and
December 31st, 2016 in the ED of Meyer Children’s Hospital (Italy). Demographics, clinical status, suspected drugs,
ADR description, and its degree of seriousness were collected. Logistic regression was used to estimate the reporting odds
ratios (RORs) with 95% confidence intervals (CIs) of potential predictors of ADR seriousness.
Results: Within 5 years, we observed 834 ADRs (1100 drug-ADR pairs), of whom 239 were serious; of them, 224 led to
hospitalization. Patients were mostly treated with one drug. Among patients treated with more than one drug, 78 ADRs
presented a potential interaction. The most frequently reported ADRs involved gastrointestinal system. The most frequently
reported medication class was antinfectives. Risk of serious ADR was significantly lower in children and infants compared to
adolescents (ROR 0.41 [95% CI: 0.27–0.61] and 0.47 [0.32–0.71], respectively), and it was significantly increased in subjects
exposed to more than one drug (ROR 1.87 [1.33–2.62] and 3.01 [2.07–4.37] for subjects exposed to 2 and 3 or more drugs,
respectively). Gender, interactions and off-label drug use did not influence the risk of serious ADRs.
Conclusion: Active surveillance in pharmacovigilance might represent the best strategy to estimate and characterize the
clinical burden of ADRs in children.
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Background
Adverse drug reactions (ADRs) are the most common
cause of iatrogenic harm in health care and have re-
cently received attention in national patient safety initia-
tives [1]. Moreover, ADRs are a significant cause of
emergency department (ED) visits [2].
Most studies on hospital admissions related to medica-
tion use focus on adult patients [3–8]. Fortunately, the
burden of ADR-related ED admissions in children seems
to be lower than observed in adults (5%–25% of all ED
admissions) [3, 9], ranging from 0.4% to 10.3% of all
children with a pooled estimate of 2.9% [10].
In this context, risk factors for ADRs in children are
still poorly characterized. In fact, pharmacotherapy in
children differs from adults, thus the spectrum of ADRs
in children may differ as well [11], and certain subgroups
are at higher risk, such as children exposed to cancer
chemotherapy [12]. Furthermore, children are more
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often exposed to off-label medications, that potentially
represent a greater risk for ADRs [13]. Because part of
these medication-related events may be preventable [14],
more knowledge on occurrence and content of ADRs in
pediatric setting is necessary, with efforts focused on redu-
cing medication errors and inappropriate prescribing [1].
EDs are an essential part of health care systems, serv-
ing as an interface between hospitals and communities,
and could constitute the most important source of infor-
mation about the frequency, seriousness, and economic
burden of ADRs [15, 16].
Preventing ADRs and their related ED admissions in
outpatients remains a public health and a patient safety
challenge. Aims of this study are to describe frequency,
preventability and seriousness of ADRs in children, and
to evaluate the association between specific factors and
the reporting of ADRs, by means of a 5-years long active
pharmacovigilance study in ED.
Methods
This is a retrospective study performed on reports of sus-
pected ADRs collected between January 1st, 2012 and De-
cember 31st, 2016 in the ED of Anna Meyer Children’s
University Hospital of Florence (Italy), as part of the study
“Epidemiological Monitoring of Adverse Drug Reactions
in Emergency Department” (MEREAFaPS), an on-going
multicenter Italian active pharmacovigilance project. We
analyzed all suspected ADRs reported from patients hav-
ing at least one drug- or vaccine-related event.
All suspected ADRs leading to ED admission were
identified from ED clinical charts and hospitalization
data from the hospital discharge database. For each ADR
report, we recorded demographic characteristics (age,
gender, ethnic group), and patient clinical status on ED
admission. Anatomical Therapeutic Chemical (ATC)
classification system was used to code ongoing therapy
(suspect and concomitant medications, administration
route, therapy duration, and dosages). We also recorded
all therapeutic indications of suspected drugs. The de-
scription of the ADR according to diagnosis and symp-
toms, was coded using the Medical Dictionary for
Regulatory Activities (MedDRA) and organized by Sys-
tem Organ Class (SOC) [17]. ADR seriousness was clas-
sified according to the World Health Organization
(WHO) criteria [17] as fatal, life-threatening, or requir-
ing hospitalization of the patient, or causing serious/per-
manent disability.
The primary outcome was the frequency of total and
serious ADRs leading to ED admission. The most fre-
quently reported SOC and ATC classes were also evalu-
ated. For each drug-ADR pair, causality and preventability
(categorized as definitely or probably preventable, or not
preventable) were assessed using the Naranjo [18] scale
and Schumock and Thornton [19] algorithm, respectively.
For the causality assessment of vaccine-related ADRs, the
specific WHO [20, 21] algorithm was used. Data on medi-
cations were also analysed for drug-drug interactions
(DDIs) by using the drug interaction software Microme-
dex Drug-REAX System (Thomson Reuters Healthcare
Inc., Greenwood Village, Colorado, United States), avail-
able online with restricted access [22, 23].
The specific factors associated with the reporting of
ADRs, such as age classes, sex, number of suspected
drugs, DDIs and on-label vs off-label use were also ana-
lysed. The off-label use in children was defined as the use
of a drug already covered by a Marketing Authorisation,
in an unapproved way in terms of therapeutic indication,
posology, formulation and route of administration [24].
Descriptive statistics was used to summarize data. Cat-
egorical data were reported as frequencies and percent-
ages, whereas continuous data were reported as means
with standard errors. Univariate and multivariate logistic
regression were used to estimate the reporting odds ra-
tios (RORs) with 95% confidence intervals (CIs) of po-
tential predictors of ADR seriousness. ROR values for
each variable were reported both as crude values and ad-
justed for all the other considered variables. All results
were considered to be statistically significant at p < 0.05.
Data management and statistical analysis were carried
out using STATA 14.
Tuscany approved the present study with the Notification
number 1225 - December 21, 2009. The local institutional
ethics committee of the coordinating center (Comitato
Etico di Area Vasta Nord “CEAVNO” per la Sperimenta-
zione Clinica, Azienda Ospedaliero-Universitaria Pisana)
approved the study according to the legal requirements
concerning observational studies (Study number 3055/
2010, Protocol number 45288 - August 6, 2014).
Results
During the 5-year study period, a total of 221,528 ED
admissions was evaluated; of them, 492 were ADR-
related, with an overall rate of 2.2 per 1000 ED admis-
sions. Table 1 shows data of pediatric patients who expe-
rienced an ADR-related ED admission. We observed 834
ADRs, of whom 239 were serious (28.66%) and, of them,
224 led to hospitalization. No ADR led to death. Most of
ADRs occurred in Caucasians (90.65%), with a mean pa-
tients’ age (± standard error) of 62.53 ± 2.09 months.
The male/female rate of ADRs was 1.17, i.e. comparable
to the all-cause ED admission rate observed in Meyer
Children’s University Hospital. A total of 483 ADRs (57.
91%) had an improvement and 48 (5.76%) had a
complete resolution. For 285 ADRs (34.17%) data on the
outcome were not available. Overall, patients were
mostly treated with only one drug at time of ADR occur-
rence. Among patients treated with two or more drugs,
78 ADRs (20.21%) presented a potential DDI, which was
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severe in 57 cases (14.77%). The total number of drug-
ADR pairs was 1100. Of them, 711 drug-ADR pairs were
related to non-vaccines drugs; considering causality as-
sessment, 82 were certain, 310 probable, 301 possible
and 18 in doubt. On the other hand, 389 (35.36%) were
related to vaccines; in particular, considering the evalu-
ation of causality assessment, 333 were considered as as-
sociable, 50 as undefined and 6 were not associable.
Table 2 reported the distribution of ADRs according
to SOC classification. The most frequently reported
SOCs were: gastrointestinal disorders (27.34%), followed
by general disorders and administration site conditions
(21.46%), skin and subcutaneous tissue disorders (16.
19%), nervous system disorders (12.95%) and metabol-
ism and nutrition disorders (3.60%). The majority of
ADRs for each SOC were non-serious.
The drug-ADR pairs (stratified by ATC classes, level I)
most commonly involved in ED admissions, overall and
stratified according to ADRs seriousness, preventability
and off-label use are listed in Table 3. Out of 1100 drug-
ADR pairs, 711 were not related to vaccines; of them
more than 30% were serious, 24% preventable and 8.7%
related to off-label use. The most frequently reported
ATC class was antinfectives for systemic use (ATC class
J, excluded J07*) accounting for 288 drug-ADR pairs (40.
51%). Of them, 23.96% were serious, 24.19% were pre-
ventable and 0.69% were related to off-label use. The
second most frequently reported ATC class was nervous
system medication (ATC class N), accounting for 168
drug-ADR pairs (23.63%), of whom 48.21, 48.81 and 10.
71% were serious, preventable and related to off-label
use, respectively. All other ATC classes accounted for 8.
30 to 0.56% of drug-ADR pairs.
The most frequent suspected active principles
(APs) among antinfectives for systemic use agents
and nervous system medications are reported in
Additional file 1: Table S1.
Out of 1100 drug-ADR pairs, 389 were related to
vaccines (35.36%); of them, 28% and 6.9% were ser-
ious and preventable, respectively (Table 3). The most
Table 1 Characteristics of pediatric patients admitted to ED for
ADR
Tot ADRs N (% out of 834)
N involved patients 492
N ADRs/patients
1 256 (52.03)
2 155 (31.50)
3+ 81 (16.46)
Age
Mean ± standard error, months 62.53 ± 2.09
Age classes
New-borns (< 1 month) 7 (0.84)
Infants (1–23 months) 332 (39.81)
Children (24–143 months) 368 (44.12)
Adolescents (144–192 months) 127 (15.23)
Sex
Male 449 (53.48)
Female 385 (46.16)
Ethnic group
Caucasian 756 (90.65)
Others 25 (3.00)
Not available 53 (6.35)
Tot number of drugs
1 448 (53.72)
2 255 (30.58)
3+ 131 (15.71)
Seriousness
Hospitalization 224 (26.86)
Congenital abnormalities/ Deficit 1 (0.12)
Other clinically relevant conditions 14 (1.68)
Outcome
Complete resolution 48 (5.76)
Improvement 483 (57.91)
Invariant situation/worsening 18 (2.16)
Not available 285 (34.17)
Drug-drug interactionsa
No 308 (79.79)
Yes 78 (20.21)
Mild 4 (1.04)
Moderate 17 (4.40)
Severe 57 (14.77)
Tot drug ADR-pairs N
(% out of 1100)
Drugs (vaccines excluded) 711 (64.64)
Causality
In doubt 18
Possible 301
Table 1 Characteristics of pediatric patients admitted to ED for
ADR (Continued)
Tot ADRs N (% out of 834)
Probable 310
Certain 82
Vaccines 389 (35.36)
Causality
Not associable 6
Undefined 50
Associable 333
aPercentage calculated on the total number of ADRs occurred in patients with
more than one drug
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Table 2 Distribution of ADRs according to SOC classification
Tot ADRs N (% out of 834) Serious ADRs N (% out of corresponding SOC)
SOC
Gastrointestinal disorders 228 (27.34) 68 (29.82)
General disorders and administration site conditions 179 (21.46) 41 (23.56)
Skin and subcutaneous tissue disorders 135 (16.19) 17 (12.59)
Nervous system disorders 108 (12.95) 45 (41.67)
Metabolism and nutrition disorders 30 (3.60) 11 (36.67)
Respiratory, thoracic and mediastinal disorders 27 (3.24) 8 (29.63)
Musculoskeletal and connective tissue disorders 27 (3.24) 11(40.74)
Psychiatric disorders 18 (2.16) 7 (38.89)
Eye disorders 13 (1.56) 5 (38.46)
Cardiac disorders 12 (1.44) 5 (41.67)
Ear and labyrinth disorders 10 (1.20) 1 (10)
Investigations 8 (0.96) 3 (37.50)
Infections and infestations 8 (0.96) 1 (12.50)
Vascular disorders 7 (0.84) 2 (28.57)
Injury, poisoning and procedural complications 7 (0.84) 4 (57.14)
Blood and lymphatic system disorders 5 (0.60) 3 (60.00)
Reproductive system and breast disorders 4 (0.48) 0 (0.00)
Renal and urinary disorders 4 (0.48) 3 (75.00)
Immune system disorders 3 (0.36) 3 (100.00)
Surgical and medical procedures 1(0.12) 1 (100.00)
Table 3 Distribution of drug-ADR pairs according to ATC classification (level I), overall and stratified according to seriousness, preventability
and off-label use
Tot drug-ADR pairs
N (% out of 1100)
Seriousness
N (% out of ATC level I)
Preventability
N (% out of ATC level I)
Off-label use
N (% out of ATC level I)
Related to Vaccines 389 (35.36) 109 (28.02) 27 (6.94) –
Not related to Vaccines (ATC level I) 711 (64.64) 226 (31.79) 172 (24.19) 62 (8.72)
J - Antinfectives for systemic use
(excluded vaccines - J07)
288 (40.51) 69 (23.96) 15 (5.21) 2 (0.69)
N - Nervous system 168 (23.63) 81 (48.21) 82 (48.81) 18 (10.71)
A - Alimentary tract and metabolism 59 (8.30) 16 (27.12) 25 (42.37) 3 (5.08)
M - Musculoskeletal system 53 (7.45) 18 (33.96) 9 (16.98) 0 (0.00)
C - Cardiovascular system 39 (5.49) 17 (43.59) 22 (56.41) 18 (46.15)
H - Systemic hormonal preparations 31 (4.36) 7 (22.58) 6 (19.35) 5 (16.13)
R - Respiratory system 27 (3.80) 3 (11.11) 2 (7.41) 3 (11.11)
L - Antineoplastic and immunomodulating agents 13 (1.83) 4 (30.77) 2 (15.38) 2 (15.38)
B- Blood and blood-forming organs 11 (1.55) 6 (54.55) 3 (27.27) 5 (45.45)
D - Dermatologicals 10 (1.41) 3 (30.00) 1 (10.00) 0 (0.00)
G - Genitourinary system and sex hormones 4 (0.56) 2 (50.00) 4 (100.00) 4 (100.00)
P - Antiparasitic products 4 (0.56) 0 (0.00) 0 (0.00) 0 (0.00)
S - Sensory organs 4 (0.56) 0 (0.00) 1 (25.00) 2 (50.00)
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frequent suspected vaccines were Meningococcus B,
multicomponent vaccine (n = 67, of whom 32.84% ser-
ious), Diphtheria-haemophilus influenzae B-pertussis-
poliomyelitis-tetanus-hepatitis B (n = 57, of whom 45.
61% serious), and Pneumococcus, purified polysaccha-
rides antigen conjugated (n = 55, of whom 32.73% ser-
ious) (Additional file 2: Table S2).
Table 4 reports the distribution of serious and non-
serious drug-ADR pairs and the potential associations
between serious ADR risk and age, gender, total number
of pharmacological treatments and presence of DDIs.
On-label and off-label use and relative associations were
also evaluated. Seriousness of ADRs significantly differed
among age classes and according to the total number of
drugs administered (p < 0.001). Risk of having an ADR
reported as serious was significantly lower in children
and infants compared to adolescents (adjusted ROR of 0.
41 [95% CI: 0.27–0.61] and 0.47 [0.32–0.71], respect-
ively). Risk of serious ADRs was significantly increased
in subjects exposed to more than one drug (adjusted
ROR of 1.87 [1.33–2.62] and 3.01 [2.07–4.37] for sub-
jects exposed to 2 and 3 or more drugs, respectively)
compared to subjects exposed to only one drug. On the
other hand, the gender, the presence of DDIs and the
on-label or off-label drug use did not influence the risk
of having an ADR reported as serious.
Discussion
This study aimed to explore the frequency, preventability
and seriousness of ADRs observed over a 5-year period
in a single pediatric center in Italy, and to our know-
ledge it is the first study focused on serious ADRs with
the aim of addressing the factors associated with the
reporting of this kind of ADRs, in an Italian clinical
pediatric setting.
In the present analysis, the rate of ADR-related ED ad-
missions was 2.2 per 1000 admissions, notably lower than
what is generally reported in literature (0.4% to 10.3% of
all children, pooled estimate of 2.9%) [10]. In fact in a
large systematic review [10], the rates of ADRs causing
hospital admission ranged from 0.4% to 10.3% of all chil-
dren (pooled estimate of 2.9% (2.6%, 3.1%)). This can be
explained by the fact that we calculated the actual rate of
ADRs on all ED admissions, including also those not re-
lated to drug utilization. These findings are in keeping
with what was reported in another Italian study [25] that
showed similar results in terms of ATC classes and SOCs
most frequently associated with ADRs in children. Ac-
cording to Rosafio et al. (2017) [25], the medication clas-
ses most frequently implicated were anti-infective drugs
for systemic use (28.9%) and central nervous system
agents (22.3%). The three most common symptom mani-
festations were dermatologic conditions (46.1%), general
Table 4 Distribution of serious and non-serious drug-ADR pairs, and association between serious ADR risk and different factors,
expressed as Reporting Odds Ratio (ROR)
Non-serious drug-ADR pairs
N (% out of 765)
Serious drug-ADRs pairs
N (% out of 335)
p-value Adjusted ROR of serious ADR
[95% CI]
p-value
Age classes (FDA classification)
Adolescents (144–192 months) 86 (11.24) 72 (21.49) < 0.001 Ref
Children (24–143 months) 335 (43.79) 123 (36.72) 0.41 [0.27–0.61] < 0.001
Infants (1–23 months) 336 (43.92) 137 (40.90) 0.47 [0.32–0.71] 0.001
New-borns (< 1 month) 8 (1.05) 3 (0.90) 0.42 [0.10–1.70] 0.224
Sex
Male 353 (46.14) 144 (42.99) 0.333 Ref.
Female 412 (53.86) 191 (57.01) 0.77 [0.59–1.02] 0.072
Tot number of drugs
1 347 (45.36) 101 (30.15) < 0.001 Ref.
2 276 (36.08) 128 (38.21) 1.87 [1.33–2.62] < 0.001
3+ 142 (18.56) 106 (31.64) 3.01 [2.07–4.37] < 0.001
Drug-drug interactions
No 268 (64.11) 165 (70.51) 0.097
Yes 150 (35.89) 69 (29.49) 0.77 [0.54–1.11] 0.166
Off-label vs on-label usea
On-Label 447 (92.36) 201 (88.94) 0.133 Ref.
Off-label 37 (7.64) 25 (11.06) 1.56 [0.90–2.73] 0.115
Adjusted ROR values are shown along with the respective 95% Confidence Intervals
aCalculated only on non-vaccine medications
Lombardi et al. BMC Pharmacology and Toxicology  (2018) 19:16 Page 5 of 8
disorder and administration site conditions (29.7%) and
gastrointestinal symptoms (16.0%).
Among the ADR reports collected in our study, “Anti-
nfectives for systemic use” were the most common
drugs, in agreement with a major national ADRs over-
view conducted in Italy in the last decade [16, 26]. In
particular, amoxicillin and amoxicillin/clavulanate were
the most frequently involved APs. This evidence could
be attributable to the fact that in Tuscany amoxicillin
and amoxicillin/clavulanate are generally the most pre-
scribed antibiotics in the pediatric population (14.06 and
23.08 defined daily dose/1000 inhabitants per day, re-
spectively) [27]. The most reported SOC in the present
study was “Gastrointestinal disorders”, whereas in litera-
ture “Skin and subcutaneous tissue disorders” is gener-
ally the first SOC to be reported in this population
subset [28]. This discrepancy could be related to the fact
that dermatological ADRs are generally less serious than
gastrointestinal ones, and therefore could be mainly
managed by out-of-hospital healthcare professionals ra-
ther that in EDs.
Regarding vaccine-related ED admission, this study
showed a higher number of drug-ADR pairs for “Menin-
gococcus B multicomponent vaccine” than reported by
Rosafio et al. [25]. This data are not surprising given the
peculiar Tuscan scenery of meningococcal B disease
high incidence and the correlated high vaccination rate
in children in the past few years [29]. Anyway, in our
study the most common ADRs related to vaccines were
fever, injection-site hypersensitivity and edema, and local
vasodilatation (data not shown), that cannot be consid-
ered life-threatening, although they led to an ED admis-
sion. Thus, considering the high number of vaccine
doses administered in Tuscany every year [30], the total
number of vaccines-related ADRs detected in the
present study is reasonably low and provides a general
perception of safety of vaccination in children [31].
The rate of serious ADRs compared to non-serious
ones, was lower than observed in other studies, performed
in both general and pediatric populations [17, 28]. The
lower rate of serious ADRs in this sample may indicate a
better quality and safety of prescribing in the setting eval-
uated. Among the drug classes that deserve particular at-
tention in terms of preventable ADRs, there are
“Antinfectives for systemic use” (ATC class J) and “Ner-
vous system medications” (ATC class N). The clinical
evaluation of the collected ADR reports identified several
cases of misuse and abuse due to accidental drug ingestion
for class N. Unintentional exposure among children is an
important public health problem [32]. One out of 180
two-year-old child visits an ED for a medication poisoning
each year [33], and, during 2010–2011, an average of 1499
children/year aged less than 6 years were evaluated in ED
in the United States for unintentional exposure to drugs,
including agents of ATC class N [34]. In this context, our
evidences underline the importance of careful drug man-
agement by parents and caregivers [35], with the final goal
of improving the strategies to prevent these kind of ad-
verse events [36].
This study also showed a correlation between the risk
of serious ADR and age classes. Children and infants
had a significantly lower risk of serious ADRs compared
to adolescents, as reported in other studies [37, 38]. To
the best of our knowledge, no other publications have
previously reported age as a risk factor for serious ADR-
related ED admission in children. In general, age-based
analyses do not follow a clear pattern and are difficult to
evaluate due to the variety of age classifications [10].
Healthcare professionals have to consider important fac-
tors related to age, such as pharmacokinetic and phar-
macodynamic differences during children growth (i.e.,
immature tubular function and hypoalbuminemia in ne-
onates, immaturity of blood brain barrier, reduced me-
tabolism and liver function, etc.) [39].
Concerning risk factors associated with ADRs in chil-
dren, polypharmacy was found as a potential predictor
of adverse events. Multiple regression analysis showed a
statistically significant correlation between polypharmacy
(use of more than 3 drugs) and the risk of presenting to
the ED for a serious ADR. Our results are consistent
with several published investigations conducted in
pediatric patients that also show polypharmacy to be an
important factor that predisposes to ADRs [38]. Poly-
pharmacy as a risk factor for ADRs is well characterized
in adults and older subjects [40] and descriptive data are
also available in children [41], but the risk of serious
ADRs had not been addressed previously.
Off-label prescribing has been widely observed in chil-
dren [42]. However, administration of a drug outside the
conditions assessed during clinical trials may result in
ADRs [43]. The present study shows no statistically sig-
nificant difference between on-label and off-label use in
terms of ADRs occurrence. Our evidence confirms the
data already reported by Palmaro and colleagues on the
safety of off-label drug utilization [44].
It is well known that the lack of reliable data on drug
safety in the pediatric population is associated with spe-
cific issues, among which are the lack of dedicated clinical
trials and the non-linear development of pharmacokinetic
parameters [45]. Serious ADRs are generally not observed
during pediatric clinical trials, especially in case of a la-
tency period before onset [46], and in children as in adults
it is not possible to fully investigate the spectrum of ser-
ious ADRs prior authorization of most medications [47].
Pharmacovigilance spontaneous reporting systems are
subjected to under-reporting of ADRs, including serious
ones [48]. Thus, an active pharmacovigilance study like
the one presented here represents one of the best
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strategies to systematically collect, analyze and interpret
data on ADRs [17], by means of protocols designed to ac-
tively detect ADRs on an ongoing basis within a defined
group of people (i.e., children in ED).
The present study has several points of strength. First,
we used a computerized monitoring programs and all
participants were specifically trained healthcare profes-
sionals, who systematically analyzed each single ED clin-
ical record. Furthermore, this is the first retrospective
analysis evaluating serious ADRs as cause of ED admis-
sion in children over a long period of time in Italy. How-
ever, this study has also some limitations. The
retrospective nature of our study may have led to an
underestimation of the rate of ADR-related ED admis-
sions as a result of missing documented clinical data. In-
deed, not all pediatric ADRs were identified, since not
all pediatric patients presenting an ADR, even if serious,
attend ED. Therefore, the real prevalence of ADR is not
known. Last, a control group with no ADRs was not
available and this is also a limitation with regard to as-
sessment of causality between ADRs and ED admission.
Conclusions
Serious ADRs are a relevant clinical event in children
and a challenge for pediatricians and health care sys-
tems. The present research provided new insights on the
factors that might increase the risk of serious pediatric
ADRs. Future prospective, large-sample and multicenter
studies should focus on other at-risk pediatric settings
such as oncology, hematology, neurology, etc. to better
understand the impact of ADRs and the effect of pro-
grammed preventive actions. In this context, we believe
that active surveillance in pharmacovigilance might rep-
resent the best strategy to estimate and characterize the
clinical burden of ADRs in children, with the final goal
of improving the appropriateness of prescribing in the
fragile population of pediatric patients.
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